InspireMD (NYSEAMERICAN:NSPR) released its quarterly earnings results on Tuesday. The medical equipment provider reported ($3.82) EPS for the quarter, missing the consensus estimate of ($2.50) by ($1.32), Fidelity Earnings reports. The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.10 million.
Shares of NYSEAMERICAN NSPR opened at $3.48 on Thursday. InspireMD has a twelve month low of $3.37 and a twelve month high of $82.00.
An institutional investor recently raised its position in InspireMD stock. Virtu Financial LLC raised its position in shares of InspireMD Inc (NYSEAMERICAN:NSPR) by 1,305.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 291,021 shares of the medical equipment provider’s stock after buying an additional 270,318 shares during the quarter. Virtu Financial LLC owned 0.77% of InspireMD worth $46,000 at the end of the most recent quarter.
TRADEMARK VIOLATION WARNING: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/2019/05/16/inspiremd-nspr-releases-quarterly-earnings-results-misses-estimates-by-1-32-eps.html.
InspireMD Company Profile
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.
See Also: Insider Trading
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.